Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Status Recruiting

Clinical Trial Summary

Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Disorders of Excessive Somnolence
Idiopathic Hypersomnia

Clinical Trial Details

NCT number	NCT05837091
Study type	Interventional
Source	Mayo Clinic
Contact	Lupe (Ray) Canez
Phone	(480)-574-2753
Email	Canez.Lupe@mayo.edu
Status	Recruiting
Phase	Phase 4
Start date	February 14, 2024
Completion date	June 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04026958` - Clarithromycin Mechanisms in Hypersomnia Syndromes	Phase 2
Completed	`NCT02512588` - A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2	Phase 2
Completed	`NCT01183312` - Flumazenil for the Treatment of Primary Hypersomnia	Phase 1/Phase 2
Completed	`NCT03597555` - Sodium Oxybate in Idiopathic Hypersomnia	Phase 2/Phase 3
Completed	`NCT03356938` - The Role of the Circadian System in Neurological Sleep-wake Disorders	N/A
Completed	`NCT03533114` - A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension	Phase 3
Active, not recruiting	`NCT03542851` - A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia	Phase 2
Completed	`NCT05156047` - A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia	Phase 3
Enrolling by invitation	`NCT05371483` - Cardiovascular and Cognitive Implications of Central Disorders of Hypersomnolence and Their Treatments
Not yet recruiting	`NCT06252571` - a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial	Phase 2
Completed	`NCT04827329` - Anesthetic Management of Patients With Chronic Sleep Disorders
Recruiting	`NCT05875974` - Ph4 PSG Combined JZP258-407	Phase 4
Recruiting	`NCT01793168` - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed	`NCT01146600` - Clarithromycin for the Treatment of Hypersomnia	Phase 2
Recruiting	`NCT04330963` - International Swiss Primary Hypersomnolence and Narcolepsy Cohort Study
Not yet recruiting	`NCT05615584` - Spectrometry (MRM) Versus I 125 Radioimmunoassay (RIA) for Quantification of Orexin-A of Patients With Hypersomnolence	N/A
Completed	`NCT04091438` - A Study of a Single Intravenous Infusion Dose of TAK-925 in Participants With Idiopathic Hypersomnia	Phase 1
Recruiting	`NCT05321355` - Mainz Register of Patients With Sleep Disorders
Active, not recruiting	`NCT05668754` - Placebo-Controlled, Double-Blind, Study to Determine the Safety and Efficacy of SDX in Patients With IH	Phase 2
Not yet recruiting	`NCT06153615` - Local Sleep in Idiopathic Hypersomnia	N/A